Last updated: September 5, 2026
Amphotericin B is a mature antifungal active ingredient with continuing clinical importance but limited conventional pharmaceutical exclusivity. The market is divided between low-cost amphotericin B deoxycholate and premium lipid formulations, primarily liposomal amphotericin B, marketed as AmBisome. Revenue is concentrated in hospital and specialty-infectious-disease channels, while demand is driven by invasive fungal infections, visceral leishmaniasis, cryptococcosis, and antifungal resistance.
The commercial value has shifted from the active ingredient to delivery technology, tolerability, supply reliability, and institutional procurement. Generic entry has eliminated most molecule-level pricing power, but lipid formulations retain higher prices because they reduce nephrotoxicity and infusion-related toxicity compared with conventional amphotericin B.
What is the current amphotericin B market structure?
Amphotericin B has three principal commercial formulations:
| Formulation |
Representative product |
Main commercial position |
Key limitation |
| Amphotericin B deoxycholate |
Generic formulations; historical Fungizone |
Lowest acquisition cost; widely used where monitoring resources exist |
Nephrotoxicity, electrolyte abnormalities, infusion reactions |
| Liposomal amphotericin B |
AmBisome |
Premium hospital product; preferred for many severe systemic infections |
High acquisition cost; manufacturing complexity |
| Amphotericin B lipid complex |
Abelcet |
Alternative lipid formulation |
Lower market visibility than AmBisome |
| Amphotericin B colloidal dispersion |
Amphocil or Amphotec |
Historical alternative lipid formulation |
Limited current commercial relevance |
AmBisome contains amphotericin B encapsulated in liposomes composed principally of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylglycerol, and cholesterol. The formulation changes the drug’s distribution and tolerability profile rather than its antifungal mechanism. The FDA label identifies indications including empiric therapy for presumed fungal infection in febrile neutropenic patients, cryptococcal meningitis in patients with HIV, visceral leishmaniasis, and selected invasive fungal infections (U.S. Food and Drug Administration [FDA], 2023a).
Conventional amphotericin B remains clinically useful because the ingredient is inexpensive and has broad antifungal activity. Liposomal amphotericin B commands a premium because hospitals value reduced renal toxicity, lower infusion burden in some settings, and use in high-risk patients.
How large is the amphotericin B market?
Public financial reporting does not provide a single, audited global market figure for all amphotericin B products. The market is fragmented across generic manufacturers, government tenders, branded lipid formulations, hospital purchases, and products sold in emerging markets.
The commercially relevant revenue pools are:
- Generic amphotericin B deoxycholate, which is price-sensitive and tender-driven.
- Liposomal amphotericin B, which carries the largest revenue per treatment course.
- Amphotericin B lipid complex, which competes in selected hospitals and countries.
- Public-health procurement for visceral leishmaniasis and other neglected diseases.
AmBisome is the principal premium product. Gilead Sciences acquired the product through its purchase of Nexstar Pharmaceuticals in 1999 and has continued to market it globally. Gilead reports AmBisome revenue as a product category in its annual filings, although the company’s public reporting does not always provide a full market-wide view of amphotericin B sales (Gilead Sciences, 2024a).
The financial profile is structurally different from that of a conventional blockbuster:
- Unit volume is relatively low compared with chronic medicines.
- Treatment courses can be expensive because dosing is weight-based and may continue for several days.
- Sales are concentrated in hospitals and government procurement.
- Revenue is sensitive to fungal outbreaks, transplant volumes, oncology admissions, and supply interruptions.
- Generic competition limits price growth for deoxycholate products.
- Liposomal products retain pricing power where clinical guidelines favor them.
What is the financial trajectory for amphotericin B products?
Amphotericin B revenue has a mature-to-stable profile rather than a typical launch-and-decline trajectory.
Generic amphotericin B deoxycholate
Deoxycholate amphotericin B has operated as a generic hospital product for decades. Its financial trajectory is shaped by:
- Low active-ingredient cost.
- Multiple suppliers and regional registrations.
- Hospital tenders.
- Manufacturing economics for sterile injectable products.
- Periodic shortages caused by limited sterile-capacity and low margins.
The product can remain profitable for suppliers with efficient sterile manufacturing, but it is generally unattractive as a standalone innovation asset. Pricing is constrained by procurement agencies and substitution among approved injectable suppliers.
Liposomal amphotericin B
Liposomal amphotericin B has a stronger revenue profile because it addresses toxicity and administration problems associated with conventional amphotericin B. AmBisome is the most commercially established product in this segment.
Its revenue is supported by:
- Use in invasive fungal disease.
- Use in cryptococcal meningitis.
- Use in visceral leishmaniasis.
- Hospital preference in patients at elevated renal risk.
- Guideline recommendations for selected severe infections.
- Higher treatment-course value than deoxycholate amphotericin B.
Its growth is limited by:
- Generic and competing lipid formulations.
- Budget restrictions in public hospitals.
- Use of lower-cost deoxycholate products where monitoring is available.
- Competition from triazoles such as voriconazole, posaconazole, and isavuconazole.
- Echinocandins for candidemia and other Candida infections.
- The narrow population requiring amphotericin B rather than oral or less toxic intravenous alternatives.
Gilead’s financial exposure is material at the product level but small relative to its HIV, oncology, and antiviral franchises. AmBisome is not a major driver of total Gilead revenue, yet it has strategic value because it occupies a differentiated hospital niche and is used in diseases where alternatives may be limited.
What patents protect amphotericin B and AmBisome?
The original amphotericin B molecule is long off patent. The relevant intellectual property has historically covered formulations, liposomes, lipid compositions, manufacturing processes, and delivery systems.
| IP category |
Commercial relevance |
Current position |
| Amphotericin B composition of matter |
Protects the active ingredient |
Expired |
| Conventional injectable formulation |
Covers formulation and presentation |
Expired or commercially weak |
| Liposome composition |
Protects particle composition and drug loading |
Principal historical barrier for AmBisome |
| Manufacturing process |
Covers hydration, loading, purification, and sterile processing |
May remain valuable as know-how even after patent expiry |
| Method of use |
Covers selected infections or dosing regimens |
Limited incremental exclusivity because core uses are longstanding |
| Device or packaging |
May protect presentation and administration |
Limited strategic value |
AmBisome’s historical patent estate included U.S. patents covering liposomal amphotericin B compositions and preparation methods. The principal U.S. formulation patents expired years after the 1997 FDA approval, and no current composition-of-matter exclusivity protects amphotericin B itself. Patent expiry does not eliminate all barriers because liposomal manufacturing requires validated sterile processes, specialized equipment, reproducible particle characteristics, and regulatory comparability.
The FDA Orange Book should be reviewed at the product and NDA level for current listed patents. For a mature product such as AmBisome, the commercial question is less whether the active ingredient is patented and more whether an abbreviated new drug application can demonstrate pharmaceutical equivalence, bioequivalence, and comparable quality for a complex liposomal injectable (FDA, 2024a).
When does amphotericin B lose exclusivity?
Amphotericin B lost molecule-level exclusivity decades ago. FDA approvals date to the late 1950s for conventional amphotericin B products. Lipid formulations were approved later:
| Product |
Formulation |
Approximate FDA approval milestone |
Exclusivity position |
| Fungizone and successors |
Deoxycholate |
1950s |
Expired |
| Abelcet |
Amphotericin B lipid complex |
1995 |
Expired |
| Amphocil/Amphotec |
Colloidal dispersion |
1990s |
Expired |
| AmBisome |
Liposomal amphotericin B |
1997 |
Regulatory exclusivity expired; historical formulation patents expired |
FDA statutory exclusivity is no longer the central barrier for these products. The relevant competitive barriers are complex-injectable development, manufacturing validation, clinical substitution practices, and supply-chain reliability.
What is the Orange Book status of AmBisome?
AmBisome is an FDA-approved prescription liposomal amphotericin B product. It is regulated as a drug, not as a biologic, so biosimilar rules do not apply. The key regulatory pathway for a competing product is generally an ANDA or another abbreviated pathway if the formulation and reference-product requirements can be satisfied.
The Orange Book analysis should distinguish:
- The reference listed drug status of AmBisome.
- Current patent listings, if any.
- Any pediatric exclusivity or regulatory exclusivity, which are no longer expected to block ordinary generic development.
- Whether a proposed product is sufficiently equivalent to qualify for an ANDA.
- Whether FDA treats the liposomal formulation as a complex product requiring additional comparative data.
A generic developer may face greater regulatory difficulty with a liposomal injectable than with conventional amphotericin B. Liposome size, morphology, encapsulation efficiency, release characteristics, impurities, and stability can affect clinical performance. FDA’s guidance for liposome drug products identifies the need for comparative characterization and, depending on the product, additional pharmacokinetic, pharmacodynamic, or clinical evidence (FDA, 2018).
Are there Paragraph IV challenges to AmBisome?
A Paragraph IV challenge is commercially plausible only if a generic applicant identifies an unexpired Orange Book patent. The core AmBisome patents are historical and the active ingredient is off patent. The principal risk today is therefore not a classic late-stage Paragraph IV wave against a heavily protected brand.
The more important questions are:
- Whether any current patent listings remain.
- Whether a generic applicant can meet FDA’s requirements for a complex liposomal injectable.
- Whether litigation would be triggered by a new formulation or method-of-use patent.
- Whether a supplier can achieve reliable commercial-scale sterile production.
A Paragraph IV certification could still arise against a subsequently listed patent, but the mature status of the product reduces the likelihood that patent litigation alone will delay generic competition for many years.
What generic entry risks exist for liposomal amphotericin B?
Generic entry risk is moderate for conventional amphotericin B and more limited for liposomal products.
Conventional amphotericin B
Generic competition is extensive. The principal risks are price erosion and supplier substitution. Revenue can decline quickly when a hospital system awards a tender to a lower-cost manufacturer.
Liposomal amphotericin B
Liposomal generic entry is technically harder. The relevant risks include:
- Product-specific bioequivalence requirements.
- Difficulty reproducing liposome attributes.
- Sterile injectable manufacturing costs.
- Limited commercial scale.
- Need for hospital formulary adoption.
- Physician preference for the established reference product.
- Procurement requirements for uninterrupted supply.
- Potentially narrow margins after development and validation costs.
A successful generic could still produce significant price erosion because AmBisome treatment courses are expensive relative to deoxycholate. The first approved competitor would likely obtain a meaningful discount advantage, while hospitals would weigh savings against supply reliability and clinical familiarity.
How strong is the amphotericin B patent estate?
The current patent estate is weak at the molecule level and historically stronger at the formulation level.
| Patent layer |
Strength today |
Reason |
| Active ingredient |
Very weak |
Long-expired composition patents |
| Deoxycholate injection |
Very weak |
Mature generic product |
| Liposomal formulation |
Moderate historical strength; limited remaining term |
Complex formulation and prior patents |
| Manufacturing know-how |
Moderate |
Process reproducibility can be difficult to replicate |
| New delivery systems |
Potentially strong |
New lipid, nanoparticle, oral, inhaled, or targeted systems may support fresh patents |
| Method of use |
Usually limited |
Many major indications are established and broadly known |
The practical moat is operational rather than purely legal. A company with validated liposome manufacturing, global registrations, hospital contracts, and stable raw-material sourcing can defend market share after patent expiry.
What manufacturing and supply-chain barriers affect the market?
Amphotericin B products are sterile injectables. Manufacturing barriers include:
- Control of particle size and distribution.
- Consistent drug encapsulation.
- Aseptic filling.
- Sterility assurance.
- Control of residual solvents and impurities.
- Stability through transportation.
- Specialized lipid raw materials.
- Batch-release testing.
- Regulatory comparability for post-approval changes.
Supply risk is elevated because sterile injectable markets often have few economically viable suppliers. A low-priced generic may become commercially unattractive if raw-material costs rise or a facility experiences a regulatory shutdown. This dynamic can produce shortages even after patents expire.
For visceral leishmaniasis, procurement economics are different. Public-health organizations and governments may negotiate prices well below private-market levels. WHO guidance recognizes liposomal amphotericin B as an important treatment option, but affordability and distribution remain central commercial constraints (World Health Organization, 2022).
How does amphotericin B compare with newer antifungal drugs?
| Product class |
Strength versus amphotericin B |
Commercial effect |
| Triazoles |
Oral administration and lower toxicity in many settings |
Reduce amphotericin use when susceptibility and clinical status permit |
| Echinocandins |
Favorable safety profile for many Candida infections |
Displace amphotericin in candidemia |
| Isavuconazole |
Broad use with differentiated safety and administration profile |
Competes in selected mold and invasive fungal infections |
| Amphotericin B lipid formulations |
Broad activity and established use in severe disease |
Retain value where rapid fungicidal therapy or resistant infection is important |
| Conventional amphotericin B |
Low acquisition cost |
Remains relevant in resource-constrained settings |
Amphotericin B retains an important role in cryptococcal meningitis, mucormycosis, visceral leishmaniasis, and selected refractory or resistant infections. Its broad activity and long clinical history protect demand, but toxicity and intravenous administration limit expansion.
Which companies compete in amphotericin B?
Competition is divided between branded lipid products and generic injectable suppliers.
- Gilead Sciences: AmBisome.
- Generic manufacturers: suppliers of amphotericin B deoxycholate and, in some markets, lipid formulations.
- Specialty hospital suppliers: regional producers of injectable antifungals.
- Public-health manufacturers: suppliers participating in leishmaniasis and infectious-disease tenders.
- Competing antifungal companies: Pfizer, Merck, Astellas, and others in triazoles and echinocandins.
The competitive landscape is regional. Product registration, tender access, local manufacturing, and hospital supply contracts matter more than global consumer branding.
What licensing deals affect amphotericin B?
The major historical transaction was Gilead’s acquisition of Nexstar Pharmaceuticals, which brought AmBisome into Gilead’s portfolio. Current commercial value depends more on manufacturing and distribution arrangements than on new molecule licensing.
Potential licensing value remains in:
- Oral amphotericin B delivery.
- Inhaled formulations.
- Targeted liposomes.
- Combination products.
- Improved delivery for neglected tropical diseases.
- Formulations that reduce nephrotoxicity and infusion reactions.
A new delivery system could create a stronger patent position than conventional amphotericin B, but development risk is high because the active ingredient is generic and clinical differentiation must be demonstrated against established lipid formulations.
What generic launch scenarios are most likely?
Scenario 1: Continued generic deoxycholate competition
This is the base case. Prices remain low, suppliers compete through tenders, and shortages occur periodically when margins do not support multiple manufacturers.
Scenario 2: Limited liposomal generic entry
One or more regional or global manufacturers launch a liposomal competitor after completing complex formulation and regulatory work. AmBisome pricing declines, but the reference product retains share through clinical familiarity and supply reliability.
Scenario 3: New delivery technology
A company introduces oral, inhaled, or targeted amphotericin B. This would expand the addressable market only if the product improves safety, outpatient use, or access in diseases currently requiring intravenous therapy.
Scenario 4: Demand shock from resistant fungi
Rising incidence of mucormycosis, resistant Candida, or other invasive infections increases demand for amphotericin B. This would support volumes but may also increase procurement pressure and attract additional generic supply.
Key Takeaways
- Amphotericin B is a mature antifungal market with no meaningful molecule-level exclusivity.
- Conventional deoxycholate amphotericin B is highly genericized and price-sensitive.
- AmBisome remains the principal premium product because liposomal delivery reduces toxicity relative to conventional amphotericin B.
- The strongest remaining barriers are complex liposome manufacturing, sterile production, regulatory comparability, and hospital procurement.
- AmBisome’s historical formulation patents have expired or lost practical exclusivity value.
- Paragraph IV litigation is less important than the technical difficulty of developing a substitutable liposomal injectable.
- Biosimilar competition does not apply because amphotericin B is a small-molecule drug.
- Gilead’s AmBisome revenue is strategically relevant but not a major contributor to total company revenue.
- The commercial outlook is stable for severe fungal infections and public-health indications, with price pressure concentrated in generic products.
- New delivery systems offer the clearest route to fresh patent protection and improved financial performance.
FAQs
Is amphotericin B still profitable after patent expiry?
Yes. Profitability remains possible through premium lipid formulations, hospital contracts, public-health tenders, and efficient sterile manufacturing. Conventional deoxycholate products generally have lower margins.
Is AmBisome a biologic or a biosimilar reference product?
No. AmBisome is a liposomal formulation of the small-molecule drug amphotericin B. Biosimilar regulation does not apply.
Can a generic company copy AmBisome immediately after patent expiry?
No. Patent expiry does not remove the need to demonstrate equivalent quality and performance for a complex liposomal injectable. Manufacturing and regulatory requirements remain substantial.
Which amphotericin B formulation has the strongest commercial position?
Liposomal amphotericin B, particularly AmBisome, has the strongest commercial position by value. Deoxycholate amphotericin B has the broadest generic availability by volume.
What could increase future amphotericin B revenue?
Growth could come from resistant fungal infections, expanded access to visceral leishmaniasis treatment, improved oral or inhaled delivery, and new formulations that reduce renal toxicity or permit outpatient administration.
References
-
Gilead Sciences, Inc. (2024a). 2023 annual report. Gilead Sciences.
-
U.S. Food and Drug Administration. (2018). Liposome drug products: Chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation: Guidance for industry. FDA.
-
U.S. Food and Drug Administration. (2023a). AmBisome (amphotericin B) liposome for injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. FDA.
-
World Health Organization. (2022). WHO guidelines for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia. WHO.
